1
|
Vilimas T, Fullmer B, Chapman A, Pauly R, Chang TC, Chen L, Das B, Karlovich C, Evrard Y, Hollingshead M, Stotler H, Ahalt-Gottholm M, Grinnage-Pulley T, Williams M, Doroshow JH. Abstract 973: Comparative single cell transcriptome profiling of primary tumors, CTCs and metastatic sites from a bladder cancer PDX model. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A PDX bladder cancer model, BL0293-F563, spontaneously metastasizes to the liver and bone, and sheds high numbers of circulating tumor cells (CTCs). This PDX model provides a unique opportunity to explore the relationships between primary tumors, CTCs, and metastases.
Methods: BL0293-F563 tumors (available from the NCI Patient-Derived Models Repository [https://pdmr.cancer.gov/] and originally developed by Jackson Laboratories) were implanted into NSG mice, and primary tumors, metastatic nodules in the liver, and blood were collected at maximal allowable tumor burden. Tumor tissue was dissociated using Miltenyi Tumor Dissociation Kit with OctoDissociator, and Human CTCs were enriched from mouse blood through negative selection with anti-mouse CD45 and anti-mouse MHC-1 magnetic beads. Single cell sequencing was done using 10X Genomics 3’ gene expression assay v3.1. Data processing and analysis was done using 10X Genomics’ Cell Ranger pipeline, Seurat, and cNMF.
Results: single cell RNAseq data from primary tumors, CTCs, and metastases from 9 mice were aggregated into a single dataset, and cells were classified into 17 clusters using Seurat FindNeighbors. All clusters contained cells from multiple sites (primary tumor, CTCs, metastases), but three clusters were enriched in CTCs and one cluster was composed of mostly primary tumor cells. All clusters exhibited epithelial-like gene expression signature scores, suggesting that CTC shedding was occurring without prominent epithelial-mesenchymal transition. CTC-enriched clusters showed elevated expression of RHO pathway genes, implicating ameboid-like migration in CTC shedding in this PDX model. Consistent with expected differences in oxygenation states, CTC-enriched clusters exhibited a lower hypoxia gene expression score than primary tumor and metastasis-enriched clusters. CTC-enriched clusters also showed higher expression of oxidative phosphorylation genes, suggesting metabolic differences between CTCs and cells from other sites. Additionally, two of three CTC-enriched clusters had elevated expression of mitosis-associated genes, indicating that at least some subpopulations of CTCs are actively cycling. A metastasis suppressor gene KISS1 was expressed in a subset of primary tumor cells but undetectable in CTCs, suggesting that KISS1 expression loss occurs before CTC shedding.
Conclusions: Utilizing single cell gene expression profiling, we have linked the gene expression profile of CTCs to specific cell subpopulations in primary tumors and metastases. We show that CTC-enriched cell clusters appear to maintain an epithelial phenotype. Subpopulations of CTC cells exhibit enrichment of motility-associated transcripts and features of active cell cycling. Our results implicate a known metastasis suppressor gene KISS1 in CTC shedding and metastatic dissemination in this PDX model.
Citation Format: Tomas Vilimas, Brandie Fullmer, Alyssa Chapman, Rini Pauly, Ting-Chia Chang, Li Chen, Biswajit Das, Chris Karlovich, Yvonne Evrard, Melinda Hollingshead, Howard Stotler, Michelle Ahalt-Gottholm, Tara Grinnage-Pulley, Mickey Williams, James H. Doroshow. Comparative single cell transcriptome profiling of primary tumors, CTCs and metastatic sites from a bladder cancer PDX model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 973.
Collapse
Affiliation(s)
- Tomas Vilimas
- 1Frederick National Lab for Cancer Research, Frederick, MD
| | | | - Alyssa Chapman
- 1Frederick National Lab for Cancer Research, Frederick, MD
| | - Rini Pauly
- 1Frederick National Lab for Cancer Research, Frederick, MD
| | | | - Li Chen
- 1Frederick National Lab for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Lab for Cancer Research, Frederick, MD
| | | | - Yvonne Evrard
- 1Frederick National Lab for Cancer Research, Frederick, MD
| | | | - Howard Stotler
- 1Frederick National Lab for Cancer Research, Frederick, MD
| | | | | | | | | |
Collapse
|
2
|
Vilimas T, Fullmer B, Chapman A, Chen L, Chang TC, Pauly R, Das B, Karlovich C, Evrard YA, Stotler H, Gottholm-Ahalt MM, Grinnage-Pulley T, Hollingshead MG, Doroshow JH, Williams PM. Abstract P097: Comparative single cell transcriptome profiling of primary tumors, CTCs and metastatic sites from a bladder cancer PDX model. Mol Cancer Ther 2021. [DOI: 10.1158/1535-7163.targ-21-p097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A PDX bladder cancer model, BL0293-F563, grows large subcutaneous tumors, spontaneously metastasizes to the liver and bone, and sheds high numbers of circulating tumor cells (CTCs). This PDX model provides a unique opportunity to explore the relationships between primary tumors, CTCs and metastatic cell subpopulations. Methods: BL0293-F563 tumors (available from the NCI Patient-Derived Models Repository [https://pdmr.cancer.gov/] and originally developed by Jackson Laboratories) were implanted into NSG mice and and primary tumors, metastatic nodules in the liver, and blood were collected at maximal allowable tumor burden. Tumor tissue was dissociated using Miltenyi Tumor Dissociation Kit with OctoDissociator, and Human CTCs were enriched from whole mouse blood through negative selection with anti-mouse CD45 and anti-mouse MHC-1 magnetic beads. Single cell sequencing was done using 10X Genomics 3’ gene expression assay v3.1. Sequencing libraries were prepared using 10X Genomics Chromium and 3’ gene expression kit v3.1. Data processing and analysis was done using 10X Genomics’ Cell Ranger pipeline, Seurat, and consensus non-negative matrix factorization. Results: Using Seurat FindNeighbors, cells in the aggregated dataset were classified into 17 distinct clusters. All clusters were comprised of cells from multiple sites (primary tumor, CTCs, metastases), but three clusters were enriched in CTCs and one cluster was composed of mostly primary tumor cells. All clusters exhibited an epithelial-like gene expression signature score, suggesting that CTC shedding was occurring without prominent epithelial-mesenchymal transition. Consistent with expected differences in oxygenation states, CTC-enriched clusters exhibited a lower hypoxia gene expression score than primary tumor and metastasis-enriched clusters. CTC-enriched clusters also showed higher expression of oxidative phosphorylation genes, suggesting metabolic differences between CTCs and cells from primary tumors and metastases. Based on Human Primary Cell Atlas phenotype prediction, several clusters were associated with stem cell like phenotypes. Additionally, two of three CTC-enriched clusters had elevated expression of mitosis-associated genes, suggesting that at least some populations of CTCs are not quiescent but actively cycling. Conclusions: Utilizing single cell gene expression profiling, we have linked the gene expression profile of CTCs to specific cell subpopulations in primary tumors and metastases. We show that CTC-enriched cell clusters appear to maintain an epithelial phenotype. Subpopulations of CTC cells exhibited enrichment of stemness-associated transcripts and features of active cell cycling.
Citation Format: Tomas Vilimas, Brandie Fullmer, Alyssa Chapman, Li Chen, Ting-Chia Chang, Rini Pauly, Biswajit Das, Chris Karlovich, Yvonne A. Evrard, Howard Stotler, Michelle M. Gottholm-Ahalt, Tara Grinnage-Pulley, Melinda G. Hollingshead, James H. Doroshow, P. Mickey Williams. Comparative single cell transcriptome profiling of primary tumors, CTCs and metastatic sites from a bladder cancer PDX model [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P097.
Collapse
Affiliation(s)
- Tomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Brandie Fullmer
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Alyssa Chapman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Li Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Ting-Chia Chang
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Rini Pauly
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | - Howard Stotler
- 1Frederick National Laboratory for Cancer Research, Frederick, MD,
| | | | | | | | | | | |
Collapse
|
3
|
Evrard YA, Alcoser SY, Borgel S, Breen D, Carter J, Chase T, Chen A, Chen L, Cooley K, Das B, Delaney E, Dutko L, Ecker S, Forbes T, Georgius K, Gottholm-Ahalt MM, Grinnage-Pulley T, Hoffman S, Karlovich C, Klarmann K, Jiwani S, Mills J, Morris M, Mullendore M, Newton D, Rivera G, Stotler H, Stottlemyer J, Styers S, Timme CR, Trail D, Uzelac S, Vilimas T, Walsh T, Walters N, Williams PM, Hollingshead MG, Doroshow JH. Abstract 3010: Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-3010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The National Cancer Institute's Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) is performing a large-scale preclinical study with 39 patient-derived xenograft (PDX) models of rare cancers (including mesothelioma, MPNST, osteosarcoma, Merkel cell carcinoma) treated with 56 novel therapeutic combinations (targeted and cytotoxic agents) in an exploratory, n-of-4 arm, study design. Drug combinations with additive activity may undergo clinical evaluation in patients with rare cancers. PDX tumors are treated with a set of 8 combinations plus relevant vehicle controls while in parallel enough PDXs are serially passaged for the next passage and drug set. Every serial passage undergoes several quality control assessments that serve as go/no-go criteria. Combinations that show promising responses (e.g., regression or durable tumor growth inhibition) are repeated along with the single agent arms to determine if the response is driven by the combination or only one of the agents. We are currently at the half-way point in the overall study and here report interim results for the early combination agents that have single agent data for comparison. In a combination of a VEGFi and EGFRi, 6/37 models achieved a partial regression (30% shrinkage for more than one consecutive time point) and 17/37 had tumor growth inhibition while drug was on board. Single agent studies have been completed for 17/37 models with this combination and 7/9 responses were due to at least an additive effect of the combination. In contrast, while an HDACi + nucleoside analog combination had 16/36 responsive models, response in most of the single agent studies was due to only one of the agents. As part of this study, 3 models have been identified that have responded to at least 50% of the combinations tested possibly indicating a hypersensitive phenotype: two Merkel cell carcinomas (n=28 and 32) and one Neuroendocrine carcinoma (n=27). There is no immediate link between mechanism of action of the agents in the combinations, and the two Merkel cell carcinoma responses only had a moderate overlap. Finally, two Rhabdomyosarcoma models in the study have been the least responsive models to date. Funded by NCI Contract No. HHSN261200800001E
Citation Format: Yvonne A. Evrard, Sergio Y. Alcoser, Suzanne Borgel, Devynn Breen, John Carter, Tiffanie Chase, Alice Chen, Li Chen, Kristen Cooley, Biswajit Das, Emily Delaney, Lyndsay Dutko, Shannon Ecker, Thomas Forbes, Kyle Georgius, Michelle M. Gottholm-Ahalt, Tara Grinnage-Pulley, Sierra Hoffman, Chris Karlovich, Kimberly Klarmann, Shahanawaz Jiwani, Justine Mills, Malorie Morris, Michael Mullendore, Dianne Newton, Gloryvee Rivera, Howard Stotler, Jesse Stottlemyer, Savanna Styers, Cindy R. Timme, Debbie Trail, Shannon Uzelac, Tomas Vilimas, Thomas Walsh, Nikki Walters, P. Mickey Williams, Melinda G. Hollingshead, James H. Doroshow. Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3010.
Collapse
Affiliation(s)
- Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Devynn Breen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffanie Chase
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alice Chen
- 3National Cancer Institute, Frederick, MD
| | - Li Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kristen Cooley
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Lyndsay Dutko
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Shannon Ecker
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Forbes
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kyle Georgius
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Sierra Hoffman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Justine Mills
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Malorie Morris
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Gloryvee Rivera
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Howard Stotler
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Savanna Styers
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Cindy R. Timme
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Debbie Trail
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Shannon Uzelac
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Walsh
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Nikki Walters
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | |
Collapse
|
4
|
Evrard YA, Das B, Alcoser SY, Borgel S, Breen D, Carter J, Chase T, Chen A, Chen L, Cooley K, Delaney E, Divelbiss R, Dutko L, Forbes T, Georgius K, Gottholm-Ahalt M, Grinnage-Pulley T, Hoffman S, Karlovich C, Jiwani S, Mills J, Morris M, Mullendore M, Newton D, Patidar R, Rivera G, Stotler H, Stottlemyer J, Styers S, Trail D, Uzelac S, Vilimas T, Walke A, Walsh T, Walters N, Wang P, Williams PM, Hollingshead M, Doroshow JH. Abstract 5056: Quality control efforts in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository (NCI PDMR). Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The National Cancer Institute's Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) is performing a large-scale multi-year preclinical study with 39 PDX models of rare cancers (mesothelioma, MPNST, osteosarcoma, Merkel cell carcinoma, etc) treated with 56 novel therapeutic combinations in an exploratory, n-of-4 arm, study design. Combinations that show promising responses (e.g., regression or durable inhibition of tumor growth) will be repeated along with the single agent arms to determine if the response is driven by the combination or only one of the agents. In order to do this in a timely fashion, relatively speaking, the PDX tumors are serially passaged and each passage is treated with a set of 8 combinations plus relevant vehicle control(s) while in parallel enough PDXs are retained to be expanded for the next passage and drug set. Every serial passage undergoes several quality control assessments that serve as go/no-go criteria including pathology assessment, human:mouse DNA content assessment, and low pass whole genome sequencing to determine the average fraction of genome changed compared to the original donor material. If there is a QC failure, the PDX model is restarted from early passage cryo-material (passage 1-2). An additional quality control effort is to bookend the combination studies with the first set of agents to see if tumor response is similar across passages. To date, most of the models have demonstrated a high degree of stability, though a couple of models have moved toward murine content and have been restarted from early passage material so all drug combinations can be tested. DNA and RNA are retained from all passages so a full NGS evaluation can be performed at a later date. This effort has been ongoing for over a year and the first bookend studies are beginning to be tested to determine if response at first and last passage of the study are consistent with each other, given the constraints of the inherent heterogeneity of the models themselves. Single agent studies of drug combinations that demonstrated a response in 30%-50% of the models tested are also underway to determine which combinations have a more than additive effect compared to the single agents. Promising combinations will be moved forward to early phase clinical trials for these rare cancers.
Funded by NCI Contract No. HHSN261200800001E
Citation Format: Yvonne A. Evrard, Biswajit Das, Sergio Y. Alcoser, Suzanne Borgel, Devynn Breen, John Carter, Tiffanie Chase, Alice Chen, Lily Chen, Kristen Cooley, Emily Delaney, Raymond Divelbiss, Lyndsay Dutko, Thomas Forbes, Kyle Georgius, Michelle Gottholm-Ahalt, Tara Grinnage-Pulley, Sierra Hoffman, Chris Karlovich, Shahanawaz Jiwani, Justine Mills, Malorie Morris, Michael Mullendore, Dianne Newton, Rajesh Patidar, Gloryvee Rivera, Howard Stotler, Jesse Stottlemyer, Savanna Styers, Debbie Trail, Shannon Uzelac, Thomas Vilimas, Abigail Walke, Thomas Walsh, Nicole Walters, Peng Wang, P. Mickey Williams, Melinda Hollingshead, James H. Doroshow. Quality control efforts in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository (NCI PDMR) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5056.
Collapse
Affiliation(s)
- Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Devynn Breen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffanie Chase
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alice Chen
- 2National Cancer Institute, Frederick, MD
| | - Lily Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kristen Cooley
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Lyndsay Dutko
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Forbes
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kyle Georgius
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Sierra Hoffman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Justine Mills
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Malorie Morris
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Rajesh Patidar
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Gloryvee Rivera
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Howard Stotler
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Savanna Styers
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Debbie Trail
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Shannon Uzelac
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Abigail Walke
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Walsh
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Nicole Walters
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Peng Wang
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | |
Collapse
|
5
|
Mahachi K, Kontowicz E, Anderson B, Toepp AJ, Lima AL, Larson M, Wilson G, Grinnage-Pulley T, Bennett C, Ozanne M, Anderson M, Fowler H, Parrish M, Saucier J, Tyrrell P, Palmer Z, Buch J, Chandrashekar R, Scorza B, Brown G, Oleson JJ, Petersen CA. Predominant risk factors for tick-borne co-infections in hunting dogs from the USA. Parasit Vectors 2020; 13:247. [PMID: 32404151 PMCID: PMC7218638 DOI: 10.1186/s13071-020-04118-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Accepted: 05/06/2020] [Indexed: 12/12/2022] Open
Abstract
Background Both incidence and geographical range of tick-borne disease has increased across the USA. Similar to people, dogs are hosts for Anaplasma spp., Babesia spp., Ehrlichia spp. and Borrelia burgdorferi. Dogs also share our homes and beds, making them both a sentinel for the ticks in our backyards but also increasing our exposure to ticks. Measures to better track, prevent, and/or treat tick-borne diseases in companion animals can lead to better control and prevention of human tick-borne disease. This study identifies demographic and co-infection risk factors for canine seropositivity to tick-borne infections in a cohort of hunting dogs across the USA. Results Human patterns of tick-borne disease co-infection in the USA have been predominantly driven by the geographical distribution of the tick vector. Dogs who tested seropositive for Anaplasma spp. were 1.40 times more likely (P = 0.0242) to also test seropositive for Babesia spp. and vice versa (1.60 times more likely, P = 0.0014). Dogs living in the West had 5% lower risk (P = 0.0001) for Ehrlichia spp. seropositivity compared to other regions. Controlling for age and Anaplasma spp. seroprevalence, dogs in all three other regions were 2.30 times more likely (P = 0.0216) to test seropositive for B. burgdorferi than dogs in the West. Dogs seropositive for B. burgdorferi were 1.60 times more likely (P = 0.0473) to be seropositive for Anaplasma spp. Conclusions Tick geographical distributions have a prominent impact on the regional distribution of hunting dog exposure to tick-borne diseases. Education concerning regional tick prevalence and disease risk is important for everyone, but particularly dog owners, regarding ticks in their region and protection from infection and co-infection of tick-borne pathogens as they travel or move with their dogs. Dogs are sentinel species for human exposure to ticks, and as such surveillance of canine tick-borne infections and understanding the probability that these infections might be seen together as co-infections helps predict emerging areas where people are more likely to be exposed as well.![]()
Collapse
Affiliation(s)
- Kurayi Mahachi
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Eric Kontowicz
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Bryan Anderson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Angela J Toepp
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Adam Leal Lima
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Mandy Larson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Geneva Wilson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Tara Grinnage-Pulley
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Carolyne Bennett
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Marie Ozanne
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA
| | - Michael Anderson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Hailie Fowler
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Immunology Program, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA
| | - Molly Parrish
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Jill Saucier
- IDEXX Laboratories Inc, One IDEXX Drive, Westbrook, ME, 04092, USA
| | - Phyllis Tyrrell
- IDEXX Laboratories Inc, One IDEXX Drive, Westbrook, ME, 04092, USA
| | - Zachary Palmer
- Department of Geographical and Sustainability Sciences, College of Liberal Arts & Sciences, University of Iowa, Iowa City, IA, 52242, USA
| | - Jesse Buch
- IDEXX Laboratories Inc, One IDEXX Drive, Westbrook, ME, 04092, USA
| | | | - Breanna Scorza
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA
| | - Grant Brown
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA
| | - Jacob J Oleson
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA
| | - Christine A Petersen
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA. .,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA, 52241, USA. .,Immunology Program, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.
| |
Collapse
|
6
|
Evrard YA, Newton D, Das B, Alcoser SY, Arthur K, Baldwin M, Bonomi C, Borgel S, Carter J, Chase T, Chen A, Chen L, Craig NE, Datta V, Delaney E, Divelbiss R, Dougherty K, Forbes T, Georgius K, Geraghty J, Gibson M, Gottholm-Ahalt MM, Grinnage-Pulley T, Hedger K, Hoffman S, Karlovich C, Lassoued W, Jiwani S, Mallow C, McGlynn C, Morris M, Moyer J, Mullendore M, Murphy M, Patidar R, Plater K, Radzyminski M, Scott N, Stockwin LH, Stotler H, Stottlemyer J, Styers S, Trail D, Vilimas T, Wade A, Walke A, Walsh T, Williams PM, Hollingshead MG, Doroshow JH. Abstract 4524: Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute’s Patient-Derived Models Repository (PDMR). Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The National Cancer Institute (NCI) has developed a Patient-Derived Models Repository (PDMR) comprised of quality-controlled, early-passage, clinically-annotated patient-derived tumor xenografts (PDXs), in vitro tumor cell cultures (PDCs), cancer associated fibroblasts (CAFs), and patient-derived organoids (PDOrg). NCI has focused on generating models to complement existing PDX collections and address unmet needs in the preclinical model space. These models are offered to the extramural community for research use (https://pdmr.cancer.gov), along with clinical annotation and molecular information (whole exome sequence, gene expression using RNASeq), via a publicly accessible database. Currently, over 200 PDX models, 50 PDC models, and 100 CAF models are available for distribution to the US research community. Approximately 50 PDOrg models will be released in early 2019. As part of its rare cancer initiative, the NCI is also targeting the collection of infrequently-observed tumor histologies to advance both biological investigations and drug development efforts for under-studied malignancies. Comparison of matched models, models where more than one model type are available (e.g., PDX and PDC), demonstrate a high degree of concordance across the model types. Genetic stability across the models is assessed using multiple criteria including genetic assessment of CNVs and presence of driver mutations. Optimal CNV assessment uses whole exome sequence data corrected for cellularity in the patient specimen using germline reads and corrected for cellularity in the PDX specimens by subtraction of the mouse reads. Histomorphologic comparison of PDXs and cell line xenografts (CLX) generated from in vitro PDCs and PDOrgs also overall show a high degree of concordance, though loss of features and dedifferentiation can be observed in some models. Overall these models demonstrate a high degree of conservation at the genetic and pathologic level when compared to the patient tumor. These models can provide researchers the ability to perform high- or mid-throughput screening in 2D or 3D culture followed by targeted selection of PDX models for in vivo studies. Funded by NCI Contract No. HHSN261200800001E
Citation Format: Yvonne A. Evrard, Dianne Newton, Biswajit Das, Sergio Y. Alcoser, Kaitlyn Arthur, Mariah Baldwin, Carrie Bonomi, Suzanne Borgel, John Carter, Tiffany Chase, Alice Chen, Lily Chen, Nikki E. Craig, Vivekananda Datta, Emily Delaney, Raymond Divelbiss, Kelly Dougherty, Thomas Forbes, Kyle Georgius, Joe Geraghty, Marion Gibson, Michelle M. Gottholm-Ahalt, Tara Grinnage-Pulley, Kelly Hedger, Sierra Hoffman, Chris Karlovich, Wiem Lassoued, Shahanawaz Jiwani, Candace Mallow, Chelsea McGlynn, Mallorie Morris, Jenna Moyer, Mike Mullendore, Matt Murphy, Rajesh Patidar, Kevin Plater, Marianne Radzyminski, Nicki Scott, Luke H. Stockwin, Howard Stotler, Jesse Stottlemyer, Savanna Styers, Debbie Trail, Tomas Vilimas, Anna Wade, Abigail Walke, Thomas Walsh, P. Mickey Williams, Melinda G. Hollingshead, James H. Doroshow. Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute’s Patient-Derived Models Repository (PDMR) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4524.
Collapse
Affiliation(s)
- Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Kaitlyn Arthur
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Mariah Baldwin
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Carrie Bonomi
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffany Chase
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alice Chen
- 2National Cancer Institute, Frederick, MD
| | - Lily Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Nikki E. Craig
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Kelly Dougherty
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Forbes
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kyle Georgius
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Joe Geraghty
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Marion Gibson
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Kelly Hedger
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Sierra Hoffman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Wiem Lassoued
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Candace Mallow
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chelsea McGlynn
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Mallorie Morris
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Jenna Moyer
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Mike Mullendore
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Matt Murphy
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Rajesh Patidar
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kevin Plater
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Nicki Scott
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Luke H. Stockwin
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Howard Stotler
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Savanna Styers
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Debbie Trail
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Anna Wade
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Abigail Walke
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Walsh
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | |
Collapse
|
7
|
Rintelmann CL, Grinnage-Pulley T, Ross K, Kabotso DEK, Toepp A, Cowell A, Petersen C, Narasimhan B, Pohl N. Design and synthesis of multivalent α-1,2-trimannose-linked bioerodible microparticles for applications in immune response studies of Leishmania major infection. Beilstein J Org Chem 2019; 15:623-632. [PMID: 30931004 PMCID: PMC6423605 DOI: 10.3762/bjoc.15.58] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 02/20/2019] [Indexed: 12/24/2022] Open
Abstract
Leishmaniasis, a neglected tropical disease, currently infects approximately 12 million people worldwide with 1 to 2 million new cases each year in predominately underdeveloped countries. The treatment of the disease is severely underdeveloped due to the ability of the Leishmania pathogen to evade and abate immune responses. In an effort to develop anti-leishmaniasis vaccines and adjuvants, novel carbohydrate-based probes were made to study the mechanisms of immune modulation. In this study, a new bioerodible polyanhydride microparticle was designed and conjugated with a glycodendrimer molecular probe. This molecular probe incorporates a pathogen-like multivalent display of α-1,2-trimannose, for which a more efficient synthesis was designed, with a tethered fluorophore. Further attachment of the glycodendrimer to a biocompatible, surface eroding microparticle allows for targeted uptake and internalization of the pathogen-associated oligosaccharide by phagocytic immune cells. The α-1,2-trimannose-linked bioerodible microparticles were found to be safe after administration into the footpad of mice and demonstrated a similar response to α-1,2-trimannose-coated latex beads during L. major footpad infection. Furthermore, the bioerodible microparticles allowed for investigation of the role of pathogen-associated oligosaccharides for recognition by pathogen-recognition receptors during L. major-induced leishmaniasis.
Collapse
Affiliation(s)
- Chelsea L Rintelmann
- Department of Chemistry, Indiana University Bloomington, 800 E. Kirkwood Ave., Bloomington, Indiana 47405-7102, USA
| | - Tara Grinnage-Pulley
- Department of Epidemiology, College of Public Health, University of Iowa, 105 River Street, S444 CPHB, Iowa City, Iowa 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, 2500 Crosspark Road, MTF B166 Coralville, Iowa 52241, USA.,Nanovaccine Institute, Iowa State University, 2114 Sweeney Hall, Ames, Iowa 50011-2230, USA
| | - Kathleen Ross
- Nanovaccine Institute, Iowa State University, 2114 Sweeney Hall, Ames, Iowa 50011-2230, USA.,Department of Chemical and Biological Engineering, Iowa State University, 618 Bissell Road, Ames, Iowa 50011-2230, USA
| | - Daniel E K Kabotso
- Department of Chemistry, Indiana University Bloomington, 800 E. Kirkwood Ave., Bloomington, Indiana 47405-7102, USA
| | - Angela Toepp
- Department of Epidemiology, College of Public Health, University of Iowa, 105 River Street, S444 CPHB, Iowa City, Iowa 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, 2500 Crosspark Road, MTF B166 Coralville, Iowa 52241, USA
| | - Anne Cowell
- Department of Chemistry, Indiana University Bloomington, 800 E. Kirkwood Ave., Bloomington, Indiana 47405-7102, USA
| | - Christine Petersen
- Department of Epidemiology, College of Public Health, University of Iowa, 105 River Street, S444 CPHB, Iowa City, Iowa 52242, USA.,Center for Emerging Infectious Diseases, University of Iowa Research Park, 2500 Crosspark Road, MTF B166 Coralville, Iowa 52241, USA.,Nanovaccine Institute, Iowa State University, 2114 Sweeney Hall, Ames, Iowa 50011-2230, USA
| | - Balaji Narasimhan
- Nanovaccine Institute, Iowa State University, 2114 Sweeney Hall, Ames, Iowa 50011-2230, USA.,Department of Chemical and Biological Engineering, Iowa State University, 618 Bissell Road, Ames, Iowa 50011-2230, USA
| | - Nicola Pohl
- Department of Chemistry, Indiana University Bloomington, 800 E. Kirkwood Ave., Bloomington, Indiana 47405-7102, USA.,Nanovaccine Institute, Iowa State University, 2114 Sweeney Hall, Ames, Iowa 50011-2230, USA
| |
Collapse
|
8
|
Toepp AJ, Monteiro GRG, Coutinho JFV, Lima AL, Larson M, Wilson G, Grinnage-Pulley T, Bennett C, Mahachi K, Anderson B, Ozanne MV, Anderson M, Fowler H, Parrish M, Willardson K, Saucier J, Tyrell P, Palmer Z, Buch J, Chandrashekar R, Brown GD, Oleson JJ, Jeronimo SMB, Petersen CA. Comorbid infections induce progression of visceral leishmaniasis. Parasit Vectors 2019; 12:54. [PMID: 30674329 PMCID: PMC6345068 DOI: 10.1186/s13071-019-3312-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Accepted: 01/13/2019] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Visceral leishmaniasis (VL) is a vector borne zoonotic disease endemic in humans and dogs in Brazil. Due to the increased risk of human infection secondary to the presence of infected dogs, public health measures in Brazil mandate testing and culling of infected dogs. Despite this important relationship between human and canine infection, little is known about what makes the dog reservoir progress to clinical illness, significantly tied to infectiousness to sand flies. Dogs in endemic areas of Brazil are exposed to many tick-borne pathogens, which are likely to alter the immune environment and thus control of L. infantum. RESULTS A cross-sectional study of 223 dogs from an area of Natal, in the Rio Grande do Norte, Brazil, were studied to determine the association between comorbid tick-borne disease and Leishmania infection in this endemic area. The risk of Leishmania seropositivity was 1.68× greater in dogs with tick-borne disease seropositivity compared to those without (Adjusted RR: 1.68, 95% CI: 1.09-2.61, P = 0.019). A longitudinal study of 214 hunting dogs in the USA was conducted to determine the causal relationship between infection with tick-borne diseases and progression of VL. Hunting dogs were evaluated three times across a full tick season to detect incident infection with tick-borne diseases. A logistic regression model with generalized estimating equations to estimate the parameters was used to determine how exposure to tick-borne disease altered VL progression over these three time points when controlling for other variables. Dogs infected with three or more tick-borne diseases were 11× more likely to be associated with progression to clinical VL than dogs with no tick-borne disease (Adjusted RR: 11.64, 95% CI: 1.22-110.99, P = 0.03). Dogs with exposure to both Leishmania spp. and tick-borne diseases were five times more likely to die during the study period (RR: 4.85, 95% CI: 1.65-14.24, P = 0.0051). CONCLUSIONS Comorbid tick-borne diseases dramatically increased the likelihood that a dog had clinical L. infantum infection, making them more likely to transmit infection to sand flies and people. As an important consequence, reduction of tick-borne disease exposure through topical or oral insecticides may be an important way to reduce progression and transmissibility of Leishmania infection from the canine reservoir to people.
Collapse
Affiliation(s)
- Angela J. Toepp
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Glória R. G. Monteiro
- Institute of Tropical Medicine of Rio Grande do Norte, Federal University of Rio Grande do Norte, Natal, RN 59078-970 Brazil
| | - José F. V. Coutinho
- Institute of Tropical Medicine of Rio Grande do Norte, Federal University of Rio Grande do Norte, Natal, RN 59078-970 Brazil
| | - Adam Leal Lima
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Mandy Larson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Geneva Wilson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Tara Grinnage-Pulley
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Carolyne Bennett
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Kurayi Mahachi
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Bryan Anderson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Marie V. Ozanne
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
| | - Michael Anderson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Hailie Fowler
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Immunology Program, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242 USA
| | - Molly Parrish
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Kelsey Willardson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
| | - Jill Saucier
- IDEXX Laboratories Inc., One IDEXX Drive, Westbrook, Maine 04092 USA
| | - Phyllis Tyrell
- IDEXX Laboratories Inc., One IDEXX Drive, Westbrook, Maine 04092 USA
| | - Zachary Palmer
- Department of Geographical and Sustainability Sciences, College of Liberal Arts & Sciences, University of Iowa, Iowa City, Iowa 52242 USA
| | - Jesse Buch
- IDEXX Laboratories Inc., One IDEXX Drive, Westbrook, Maine 04092 USA
| | | | - Grant D. Brown
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
| | - Jacob J. Oleson
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
| | - Selma M. B. Jeronimo
- Institute of Tropical Medicine of Rio Grande do Norte, Federal University of Rio Grande do Norte, Natal, RN 59078-970 Brazil
| | - Christine A. Petersen
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242 USA
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa 52241 USA
- Immunology Program, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242 USA
| |
Collapse
|
9
|
Toepp A, Larson M, Wilson G, Grinnage-Pulley T, Bennett C, Leal-Lima A, Anderson B, Parrish M, Anderson M, Fowler H, Hinman J, Kontowicz E, Jefferies J, Beeman M, Buch J, Saucier J, Tyrrell P, Gharpure R, Cotter C, Petersen C. Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis. Vaccine 2018; 36:6433-6441. [PMID: 30219369 DOI: 10.1016/j.vaccine.2018.08.087] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 08/03/2018] [Accepted: 08/04/2018] [Indexed: 10/28/2022]
Abstract
Better tools are necessary to eliminate visceral leishmaniasis (VL). Modeling studies for regional Leishmania elimination indicate that an effective vaccine is a critical tool. Dogs are the reservoir host of L. infantum in Brazil and the Mediterranean basin, and therefore are an important target for public health interventions as well as a relevant disease model for human VL. No vaccine has been efficacious as an immunotherapy to prevent progression of already diagnostically positive individuals to symptomatic leishmaniasis. We performed a double-blinded, block-randomized, placebo-controlled, vaccine immunotherapy trial testing the efficacy of a recombinant Leishmania A2 protein, saponin-adjuvanted, vaccine, LeishTec®, in owned hunting dogs infected with L. infantum. The primary outcome was reduction of clinical progression, with reduction of mortality as a secondary outcome. Vaccination as an immunotherapy reduced the risk of progression to clinically overt leishmaniasis by 25% in asymptomatic dogs (RR: 1.33 95% C.I. 1.009-1.786 p-value: 0.0450). Receiving vaccine vs. placebo reduced all-cause mortality in younger asymptomatic dogs by 70% (RR: 3.19 95% C.I.: 1.185-8.502 p-value = 0.0245). Vaccination of infected-healthy animals with an anti-Leishmania vaccine significantly reduced clinical progression and decreased all-cause mortality. Use of vaccination in infected-healthy dogs can be a tool for Leishmania control.
Collapse
Affiliation(s)
- Angela Toepp
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA
| | - Mandy Larson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA
| | - Geneva Wilson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA
| | - Tara Grinnage-Pulley
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA
| | - Carolyne Bennett
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA
| | - Adam Leal-Lima
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA
| | - Bryan Anderson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA
| | - Molly Parrish
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA
| | - Michael Anderson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA
| | - Hailie Fowler
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA
| | - Jessica Hinman
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA
| | - Eric Kontowicz
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA
| | | | | | - Jesse Buch
- IDEXX Laboratories Inc., Westbrook, ME, USA
| | | | | | - Radhika Gharpure
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21210, USA
| | - Caitlin Cotter
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21210, USA
| | - Christine Petersen
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA 52242, USA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA 52241, USA. http://petersen.lab.uiowa.edu/
| |
Collapse
|
10
|
Toepp A, Larson M, Grinnage-Pulley T, Bennett C, Anderson M, Parrish M, Fowler H, Wilson G, Gibson-Corely K, Gharpure R, Cotter C, Petersen C. Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial. Am J Trop Med Hyg 2018; 98:1332-1338. [PMID: 29512486 DOI: 10.4269/ajtmh.17-0888] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
In Leishmania infantum-endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.
Collapse
Affiliation(s)
- Angela Toepp
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa.,Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | - Mandy Larson
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa.,Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | - Tara Grinnage-Pulley
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa.,Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | - Carolyne Bennett
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa.,Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | - Michael Anderson
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | - Molly Parrish
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa.,Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | - Hailie Fowler
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | - Geneva Wilson
- Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa.,Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
| | | | - Radhika Gharpure
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
| | - Caitlin Cotter
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
| | - Christine Petersen
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa.,Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, Iowa
| |
Collapse
|
11
|
Grinnage-Pulley T, Mu Y, Dai L, Zhang Q. Dual Repression of the Multidrug Efflux Pump CmeABC by CosR and CmeR in Campylobacter jejuni. Front Microbiol 2016; 7:1097. [PMID: 27468281 PMCID: PMC4943160 DOI: 10.3389/fmicb.2016.01097] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Accepted: 06/30/2016] [Indexed: 12/15/2022] Open
Abstract
During transmission and intestinal colonization, Campylobacter jejuni, a major foodborne human pathogen, experiences oxidative stress. CosR, a response regulator in C. jejuni, modulates the oxidative stress response and represses expression of the CmeABC multidrug efflux pump. CmeABC, a key component in resistance to toxic compounds including antimicrobials and bile salts, is also under negative regulation by CmeR, a TetR family transcriptional regulator. How CosR and CmeR interact in binding to the cmeABC promoter and how CosR senses oxidative stress are still unknown. To answer these questions, we conducted various experiments utilizing electrophoretic mobility shift assays and transcriptional fusion assays. CosR and CmeR bound independently to two separate sites of the cmeABC promoter, simultaneously repressing cmeABC expression. This dual binding of CosR and CmeR is optimal with a 17 base pair space between the two binding sites as mutations that shortened the distance between the binding sites decreased binding by CmeR and enhanced cmeABC expression. Additionally, the single cysteine residue (C218) of CosR was sensitive to oxidation, which altered the DNA-binding activity of CosR and dissociated CosR from the cmeABC promoter as determined by electrophoretic mobility shift assay. Replacement of C218 with serine rendered CosR insensitive to oxidation, suggesting a potential role of C218 in sensing oxidative stress and providing a possible mechanism for CosR-mediated response to oxidative stress. These findings reveal a dual regulatory role of CosR and CmeR in modulating cmeABC expression and suggest a potential mechanism that may explain overexpression of cmeABC in response to oxidative stress. Differential expression of cmeABC mediated by CmeR and CosR in response to different signals may facilitate adaptation of Campylobacter to various environmental conditions.
Collapse
Affiliation(s)
- Tara Grinnage-Pulley
- Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames IA, USA
| | - Yang Mu
- Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames IA, USA
| | - Lei Dai
- Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames IA, USA
| | - Qijing Zhang
- Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames IA, USA
| |
Collapse
|
12
|
Grinnage-Pulley T, Roychoudhury R, Schaut R, Osanya A, Martinez P, Gibson-Corley K, Toepp A, Lamb I, Pohl N, Petersen CA. Immunomodulation by Leishmania-derived surface oligosaccharides promotes pro-inflammatory cytokine secretion and reduces L. major parasite load. The Journal of Immunology 2016. [DOI: 10.4049/jimmunol.196.supp.135.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Lipophosphoglycans (LPG) of Leishmania spp. are known to alter innate immune responses and be critical for parasite binding to the vector gut wall. LPG displays various oligosaccharides capping the terminal and branch apexes. However, it is unknown how these capping oligosaccharides serve as immunomodulators in the absence of a conjugated protein. Several oligosaccharides including dimannose and trimannose, were synthesized and covalently linked to latex beads to study their effect in a Leishmania infection model. In vitro incubation of activated J774 or bone marrow derived macrophages with di- and tri-mannose resulted in differential modulation of IL-12p40, a key cytokine to control intracellular pathogens by driving a Th1 response. Co-inoculation of trimannose and L. major into the footpad of C57BL/6 mice increased IL-12p40 and IFN-γ production 48 hours post-infection, a significantly Th1 skewed response. Noticeably at 14 days post-infection, L. major infected, trimannose treated mice had significantly decreased lesion size and decreased parasite load compared to infected untreated, controls. Cytokines from draining lymph node supernatants measured via Luminex at 14 days post infection showed decreased IL-12p40 and IL-10 secretion and increased IFN-γ in the co-inoculated mice. In vitro, the effects of trimannose were mediated by macrophage TLR and mannose receptors as well as T cell proliferation. Leishmania-derived trimannose represents a novel immunomodulator that provides early Th1 skewed cytokine production to control parasite load and alter the course of infection.
Collapse
|
13
|
Affiliation(s)
- Tara Grinnage-Pulley
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, United States of America
| | - Benjamin Scott
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, United States of America
| | - Christine A. Petersen
- Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, United States of America
| |
Collapse
|
14
|
Roychoudhury R, Martinez PA, Grinnage-Pulley T, Schaut RG, Petersen CA, Pohl NLB. Acid-Triggered Degradable Reagents for Differentiation of Adaptive and Innate Immune Responses to Leishmania-Associated Sugars. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201502807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
15
|
Grinnage-Pulley T, Zhang Q. Genetic Basis and Functional Consequences of Differential Expression of the CmeABC Efflux Pump in Campylobacter jejuni Isolates. PLoS One 2015; 10:e0131534. [PMID: 26132196 PMCID: PMC4488513 DOI: 10.1371/journal.pone.0131534] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Accepted: 06/03/2015] [Indexed: 11/18/2022] Open
Abstract
The CmeABC multidrug efflux transporter of Campylobacter jejuni plays a key role in antimicrobial resistance and is suppressed by CmeR, a transcriptional regulator of the TetR family. Overexpression of CmeABC has been observed in laboratory-generated mutants, but it is unknown if this phenotype occurs naturally in C. jejuni isolates and if it has any functional consequences. To answer these questions, expression of cmeABC in natural isolates obtained from broiler chickens, turkeys and humans was examined, and the genetic mechanisms and role of cmeABC differential expression in antimicrobial resistance was determined. Among the 64 C. jejuni isolates examined in this study, 43 and 21 were phenotypically identified as overexpression (OEL) and wild-type expression (WEL) levels. Representative mutations of the cmeABC promoter and/or CmeR-coding sequence were analyzed using electrophoretic mobility shift assays and transcriptional fusion assays. Reduced CmeR binding to the mutated cmeABC promoter sequences or decreased CmeR levels increased cmeABC expression. Several examined amino acid substitutions in CmeR did not affect its binding to the cmeABC promoter, but a mutation that led to C-terminal truncation of CmeR abolished its DNA-binding activity. Interestingly, some OEL isolates harbored no mutations in known regulatory elements, suggesting that cmeABC is also regulated by unidentified mechanisms. Overexpression of cmeABC did not affect the susceptibility of C. jejuni to most tested antimicrobials except for chloramphenicol, but promoted the emergence of ciprofloxacin-resistant mutants under antibiotic selection. These results link CmeABC overexpression in natural C. jejuni isolates to various mutations and indicate that this phenotypic change promotes the emergence of antibiotic-resistant mutants under selection pressure. Thus, differential expression of CmeABC may facilitate Campylobacter adaptation to antibiotic treatments.
Collapse
Affiliation(s)
- Tara Grinnage-Pulley
- Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, Iowa, United States of America
| | - Qijing Zhang
- Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, Iowa, United States of America
- * E-mail:
| |
Collapse
|
16
|
Roychoudhury R, Martinez PA, Grinnage-Pulley T, Schaut RG, Petersen CA, Pohl NLB. Acid-Triggered Degradable Reagents for Differentiation of Adaptive and Innate Immune Responses to Leishmania-Associated Sugars. Angew Chem Int Ed Engl 2015; 54:9610-3. [PMID: 26096941 DOI: 10.1002/anie.201502807] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 05/09/2015] [Indexed: 11/09/2022]
Abstract
Lipopolysaccharides (LPS) of Leishmania spp are known to alter innate immune responses. However, the ability of these sugars to specifically alter adaptive T-cell responses is unclear. To study cap sugar-T-cell interactions, pathogen mimics (namely glycodendrimer-coated latex beads with acid-labile linkers) were synthesized. Upon lysosomal acidification, linker breakdown releases glycodendrimers for possible loading on antigen presenting molecules to induce T-cell growth. T-cell proliferation was indeed higher after macrophage exposure to mannobioside or -trioside-containing glycodendrimers than to non-functionalized beads. Yet, blocking phagolysosomal acidification only reduced T-cell proliferation with macrophages exposed to beads with an acid-labile-linker and not to covalently-linked beads. These sugar-modified reagents show that oligosaccharides alone can drive T-cell proliferation by acidification-requiring presentation, most significantly in NKT receptor (CD160)-restricted T cells.
Collapse
Affiliation(s)
- Rajarshi Roychoudhury
- Department of Chemistry, Indiana University, Bloomington, IN 47405 (USA) http://www.indiana.edu/∼pohllab/
| | - Pedro A Martinez
- Department of Epidemiology, University of Iowa, Iowa City, IA 52242 (USA)
| | | | - Robert G Schaut
- Department of Epidemiology, University of Iowa, Iowa City, IA 52242 (USA)
| | | | - Nicola L B Pohl
- Department of Chemistry, Indiana University, Bloomington, IN 47405 (USA) http://www.indiana.edu/∼pohllab/.
| |
Collapse
|